Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma
Objective:. To evaluate whether this conversion rate to resectability could be increased when patients are treated with transarterial chemoembolization and hepatic arterial infusion chemotherapy (TACE-HAIC) using oxaliplatin plus fluorouracil/leucovorin. Background:. Conventional TACE (c-TACE) is a...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2021-06-01
|
| Series: | Annals of Surgery Open |
| Online Access: | http://journals.lww.com/10.1097/AS9.0000000000000057 |
| _version_ | 1797732776526479360 |
|---|---|
| author | Binkui Li, MD, PhD Jiliang Qiu, MD, PhD Yun Zheng, MD, PhD Yunxing Shi, MD Ruhai Zou, MD, PhD Wei He, MD, PhD Yichuang Yuan, MD Yuanping Zhang, MD Chenwei Wang, MD Zhiyu Qiu, MD Kai Li, MD Chengrui Zhong, MD Yunfei Yuan, MD |
| author_facet | Binkui Li, MD, PhD Jiliang Qiu, MD, PhD Yun Zheng, MD, PhD Yunxing Shi, MD Ruhai Zou, MD, PhD Wei He, MD, PhD Yichuang Yuan, MD Yuanping Zhang, MD Chenwei Wang, MD Zhiyu Qiu, MD Kai Li, MD Chengrui Zhong, MD Yunfei Yuan, MD |
| author_sort | Binkui Li, MD, PhD |
| collection | DOAJ |
| description | Objective:. To evaluate whether this conversion rate to resectability could be increased when patients are treated with transarterial chemoembolization and hepatic arterial infusion chemotherapy (TACE-HAIC) using oxaliplatin plus fluorouracil/leucovorin.
Background:. Conventional TACE (c-TACE) is a common regimen for initially unresectable hepatocellular carcinoma (HCC), which converts to curative-intent resection in about 10% of those patients. It is urgent need to investigated better regimen for those patients.
Methods:. The data of 83 initially unresectable HCC patients were examined, including 41 patients in the TACE-HAIC group and 42 patients in the c-TACE group. Their response rate, conversion rate to resection, survival outcome, and adverse events were compared.
Results:. The conversion rate was significantly better in the TACE-HAIC group than in the c-TACE group (48.8% vs 9.5%; P < 0.001). The TACE-HAIC had marginal superiority in overall response rate as compared to c-TACE (14.6% vs 2.4%; P = 0.107 [RECIST]; 65.9% vs 16.7%; P < 0.001 [mRECIST], respectively). The median progression-free survival was not available and 9.2 months for the TACE-HAIC and cTACE groups, respectively (hazard rate [HR]: 0.38; 95% confidence interval [CI], 0.20–0.70; P = 0.003). The median overall survival was not available and 13.5 months for the TACE-HAIC and c-TACE groups, respectively (HR, 0.63; 95% CI, 0.34–1.17; P = 0.132). The 2 groups had similar rates of grade 3/4 adverse events (all P > 0.05).
Conclusions:. TACE-HAIC demonstrated a higher conversion rate and progression-free survival benefit than c-TACE and could be considered as a more effective regimen for patients with initially unresectable HCC. Future prospective randomized trials are needed to confirm it. |
| first_indexed | 2024-03-12T12:19:24Z |
| format | Article |
| id | doaj.art-216a324b9f74452fb494202a810325ab |
| institution | Directory Open Access Journal |
| issn | 2691-3593 |
| language | English |
| last_indexed | 2024-03-12T12:19:24Z |
| publishDate | 2021-06-01 |
| publisher | Wolters Kluwer Health |
| record_format | Article |
| series | Annals of Surgery Open |
| spelling | doaj.art-216a324b9f74452fb494202a810325ab2023-08-30T06:08:35ZengWolters Kluwer HealthAnnals of Surgery Open2691-35932021-06-0122e05710.1097/AS9.0000000000000057202106000-00005Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular CarcinomaBinkui Li, MD, PhD0Jiliang Qiu, MD, PhD1Yun Zheng, MD, PhD2Yunxing Shi, MD3Ruhai Zou, MD, PhD4Wei He, MD, PhD5Yichuang Yuan, MD6Yuanping Zhang, MD7Chenwei Wang, MD8Zhiyu Qiu, MD9Kai Li, MD10Chengrui Zhong, MD11Yunfei Yuan, MD12From the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaFrom the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaFrom the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaFrom the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China† Department of Ultrasound, Sun Yat-Sen University Cancer Center, Guangzhou, China.From the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaFrom the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaFrom the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaFrom the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaFrom the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaFrom the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaFrom the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaFrom the * State Key Laboratory of Oncology in South China and Collaborative Innovation Center for Cancer Medicine, Department of Liver Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaObjective:. To evaluate whether this conversion rate to resectability could be increased when patients are treated with transarterial chemoembolization and hepatic arterial infusion chemotherapy (TACE-HAIC) using oxaliplatin plus fluorouracil/leucovorin. Background:. Conventional TACE (c-TACE) is a common regimen for initially unresectable hepatocellular carcinoma (HCC), which converts to curative-intent resection in about 10% of those patients. It is urgent need to investigated better regimen for those patients. Methods:. The data of 83 initially unresectable HCC patients were examined, including 41 patients in the TACE-HAIC group and 42 patients in the c-TACE group. Their response rate, conversion rate to resection, survival outcome, and adverse events were compared. Results:. The conversion rate was significantly better in the TACE-HAIC group than in the c-TACE group (48.8% vs 9.5%; P < 0.001). The TACE-HAIC had marginal superiority in overall response rate as compared to c-TACE (14.6% vs 2.4%; P = 0.107 [RECIST]; 65.9% vs 16.7%; P < 0.001 [mRECIST], respectively). The median progression-free survival was not available and 9.2 months for the TACE-HAIC and cTACE groups, respectively (hazard rate [HR]: 0.38; 95% confidence interval [CI], 0.20–0.70; P = 0.003). The median overall survival was not available and 13.5 months for the TACE-HAIC and c-TACE groups, respectively (HR, 0.63; 95% CI, 0.34–1.17; P = 0.132). The 2 groups had similar rates of grade 3/4 adverse events (all P > 0.05). Conclusions:. TACE-HAIC demonstrated a higher conversion rate and progression-free survival benefit than c-TACE and could be considered as a more effective regimen for patients with initially unresectable HCC. Future prospective randomized trials are needed to confirm it.http://journals.lww.com/10.1097/AS9.0000000000000057 |
| spellingShingle | Binkui Li, MD, PhD Jiliang Qiu, MD, PhD Yun Zheng, MD, PhD Yunxing Shi, MD Ruhai Zou, MD, PhD Wei He, MD, PhD Yichuang Yuan, MD Yuanping Zhang, MD Chenwei Wang, MD Zhiyu Qiu, MD Kai Li, MD Chengrui Zhong, MD Yunfei Yuan, MD Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma Annals of Surgery Open |
| title | Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma |
| title_full | Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma |
| title_fullStr | Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma |
| title_full_unstemmed | Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma |
| title_short | Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma |
| title_sort | conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma |
| url | http://journals.lww.com/10.1097/AS9.0000000000000057 |
| work_keys_str_mv | AT binkuilimdphd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT jiliangqiumdphd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT yunzhengmdphd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT yunxingshimd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT ruhaizoumdphd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT weihemdphd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT yichuangyuanmd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT yuanpingzhangmd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT chenweiwangmd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT zhiyuqiumd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT kailimd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT chengruizhongmd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma AT yunfeiyuanmd conversiontoresectabilityusingtransarterialchemoembolizationcombinedwithhepaticarterialinfusionchemotherapyforinitiallyunresectablehepatocellularcarcinoma |